A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
Key facts
- Who runs it
- GlaxoSmithKline
- Where
- Anniston, Austin, Charlottesville, Fair Oaks, Little Rock, Miami, Miami Lakes, Newport News, San Diego, Seattle, Stockbridge, and West Palm Beach, United StatesSee the 12 sitesAlso in 1 other country, 1 site
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 225 people, planned
- Started
- 9 Mar 2026
- Expected to end
- 3 Jun 2027
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine
- Licensed Seasonal Influenza Vaccine
- Licensed COVID-19 Vaccine
- Record updated
- 30 June 2026
Who can take part
- Age
- 65 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol independently or with the assistance of the caregiver
- Informed consent obtained from the participant prior to performance of any study-specific procedure
- A male or female 65 to 85 years of age (YoA) (inclusive) at the time of screening
- Healthy participants or medically stable patients as established by medical history and clinical examination
- Other protocol-defined inclusion criteria may apply
Who cannot take part
- History of symptomatic influenza/ SARS-CoV-2 infection confirmed by local health authority-approved testing methods within 180 days (for influenza) or 90 days (SARS-CoV-2 infection) prior to study intervention administration
- History of Guillain-Barré syndrome (GBS) within 6 weeks of receiving any vaccine
- History of hypersensitivity or allergic reaction to any previous influenza or COVID-19 vaccine
- History of hypersensitivity or allergic reaction to any previous mRNA vaccine
- Administration of any influenza vaccine within 181 days before the study intervention administration (Day -180 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration
- Administration of a SARS-CoV-2 antigen-containing vaccine in the period starting 91 days before the study intervention administration (Day -90 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration
- Administration of any mRNA-based vaccine in the period starting 29 days before the study intervention administration (Day -28 to Day 1) or planned administration within 28 days (Day 29) after the study intervention administration
- Administration of any other vaccine not foreseen by the study protocol in the period starting 29 days (Day -28 to Day 1) before the study intervention administration or planned administration within 28 days (Day 29) after the study intervention administration
- History of or current suspicion of myocarditis or pericarditis (including following administration of an mRNA vaccine); or idiopathic cardiomyopathy, or presence of any medical condition that increases the risk of myocarditis or pericarditis, including cocaine abuse, cardiomyopathy, endomyocardial fibrosis, hypereosinophilic syndrome, hypersensitivity myocarditis, eosinophilic granulomatosis with polyangiitis and persistent myocardial infection
- History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s)
- Any clinically significant laboratory abnormality
- Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required)
- Acute or unstable chronic conditions, clinically significant pulmonary, cardiovascular, or renal functional abnormality, as determined by physical examination and/or laboratory screening tests
- Current or past malignancy, unless completely resolved without clinically significant sequelae (e.g., no evidence of disease following successful treatment of basal cell carcinoma cases are allowed) for >5 years
- Other protocol-defined exclusion criteria may apply
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 65 and 85 years old?
Where in United States
Also in 1 other country, 1 site
- Anniston, AlabamaHospital not named in the registryContact: Almena Free (principal investigator)Taking people
- Austin, TexasHospital not named in the registryContact: Cary Douglass (principal investigator)Taking people
- Charlottesville, VirginiaHospital not named in the registryContact: James Clark (principal investigator)Taking people
- Fair Oaks, CaliforniaHospital not named in the registryContact: Masaru Oshita (principal investigator)Taking people
- Little Rock, ArkansasHospital not named in the registryContact: Derek Lewis (principal investigator)Taking people
- Miami, FloridaHospital not named in the registryContact: Rafael Ubeda (principal investigator)Taking people
- Miami Lakes, FloridaHospital not named in the registryContact: Jose Cardona (principal investigator)Taking people
- Newport News, VirginiaHospital not named in the registryContact: George Freeman (principal investigator)Taking people
- San Diego, CaliforniaHospital not named in the registryContact: Donald Brandon (principal investigator)Taking people
- Seattle, WashingtonHospital not named in the registryContact: Rebecca Dunsmoor-Su (principal investigator)Taking people
- Stockbridge, GeorgiaHospital not named in the registryContact: Jon Finley (principal investigator)Taking people
- West Palm Beach, FloridaHospital not named in the registryContact: Mira Baron (principal investigator)Taking people
About the trial
What the trial wants to find out
This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The study will assess any side effects or health issues, and additional blood samples will be collected at specific times to evaluate how well participants bodies build protection against the flu and COVID-19.
The 5 groups in the trial
- FLU/COVm_Dose Level 1Treatment being tested
Participants receive a single intramuscular administration of the investigational mRNA Seasonal Flu/COVID-19 combination vaccine at dose level 1 (Lowest dose).
Treatment: Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine
- FLU/COVm_Dose Level 2Treatment being tested
Participants receive a single intramuscular administration of the investigational mRNA Seasonal Flu/COVID-19 combination vaccine at dose level 2 (Medium dose).
Treatment: Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine
- FLU/COVm_Dose Level 3Treatment being tested
Participants receive a single intramuscular administration of the investigational mRNA Seasonal Flu/COVID-19 combination vaccine at dose level 3 (Highest dose).
Treatment: Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine
- Licensed Seasonal Influenza Vaccine GroupExisting treatment, for comparison
Participants receive a single intramuscular administration of a licensed seasonal Flu vaccine.
Treatment: Licensed Seasonal Influenza Vaccine
- Licensed COVID-19 Vaccine GroupExisting treatment, for comparison
Participants receive a single intramuscular administration of a licensed COVID-19 vaccine.
Treatment: Licensed COVID-19 Vaccine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1, Observer-Blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of an Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
- Criteria questions
- Built from NCT07464314, who can take part
- Record updated
- 30 June 2026